Impact of dipeptidyl peptidase-4 inhibitors on serum adiponectin: a meta-analysis.
Impact of dipeptidyl peptidase-4 inhibitors on serum adiponectin: a meta-analysis.
复制标题
二肽基肽酶 4 抑制剂对血清脂联素的影响：荟萃分析
DOI：
10.1186/s12944-016-0372-7
复制
发表时间：
2016-11-23
影响因子：
4.5
通讯作者：
Liu G
中科院分区：
文献类型：
--
作者：
Liu X;Men P;Wang Y;Zhai S;Liu G
脂联素是一种脂肪特异性蛋白，与致动脉粥样硬化的低密度脂蛋白胆固醇（LDL-C）和其他心血管危险因素如胰岛素抵抗呈负相关。因此，低水平的脂联素与糖尿病和心血管疾病的高风险相关。二肽基肽酶-4抑制剂（DPP 4 i）通过与DPP 4底物相互作用并增加血清肠促胰岛素如胰高血糖素样肽-1（GLP-1）而作为可逆性抑制剂用于治疗2型糖尿病（T2 DM）。本研究旨在评价DPP 4 i对2型糖尿病患者血清脂联素的影响。检索了PubMed、Embase和科克伦图书馆数据库，检索时间从开始到2016年2月。确定了在持续时间≥ 12周的T2 DM患者中评价DPP 4 i（西格列汀和维格列汀）与对照药物（安慰剂或活性药物比较）的随机对照试验。脂联素水平均值的加权差异采用固定或随机效应模型计算。确定了10项随机对照试验，包括1，495例受试者。与安慰剂相比，DPP 4 i（西格列汀和维格列汀）治疗显著升高脂联素水平0.74 μg/mL（95%置信区间[CI]，0.45 - 1.03），而使用活性比较的结果为0.00 μg/mL（95% CI，−0.57 - 0.56）。与活性对照组相比，维格列汀治疗使脂联素水平升高0.32 μg/mL（95% CI，−0.01至0.65），而西格列汀治疗使脂联素水平降低−0.24 μg/mL（95% CI，−1.07至0.58）。西格列汀和维格列汀可增加血清脂联素水平，但其作用并不强于传统的口服降糖药。需要进一步的更大样本量的试验来证实结果，并研究血清脂联素水平与其他DPP-4抑制剂治疗之间的相关性。PROSPERO注册号：CRD 42016037399。
Adiponectin, an adipose-specific protein, is negatively correlated with pro-atherogenic low-density lipoprotein cholesterol (LDL-C) and other cardiovascular risk factors such as insulin resistance. Therefore, low levels of adiponectin are associated with a higher risk for diabetes and cardiovascular disease. Dipeptidyl peptidase-4 inhibitors (DPP4i) have been used for the treatment of type 2 diabetes mellitus (T2DM) as reversible inhibitors through interacting with DPP4 substrate and increase serum incretins such as glucagon-like peptide-1 (GLP-1). The present study aimed to evaluate the effect of DPP4i on serum adiponectin in T2DM patients. The PubMed, Embase, and Cochrane library databases were searched from inception to February 2016. Randomized controlled trials, evaluating the DPP4i (sitagliptin and vildagliptin) versus comparator (placebo or active-comparison), in T2DM patients with duration of ≥ 12 weeks, were identified. Weighted differences in means of adiponectin levels were calculated by using a fixed or random-effects model. Ten randomized controlled trials, including 1,495 subjects, were identified. Compared with placebo, DPP4i (sitagliptin and vildagliptin) treatment significantly elevated adiponectin levels by 0.74 μg/mL (95% confidence interval [CI], 0.45 to 1.03) relative to that using an active-comparison by 0.00 μg/mL (95% CI, −0.57 to 0.56). Compared with active-comparison, vildagliptin treatment increased adiponectin levels by 0.32 μg/mL (95% CI, −0.01 to 0.65), whereas sitagliptin treatment decreased adiponectin levels by −0.24 μg/mL (95% CI, −1.07 to 0.58). Trials examining effects of other DPP4i were not found. Sitagliptin and vildagliptin increased serum adiponectin levels and had no stronger effect than traditional oral antidiabetic drugs. Further trials with larger sample size are needed to confirm the results and investigate the association between serum adiponectin levels and treatment of other DPP-4 inhibitors. Registration No in PROSPERO: CRD42016037399.
登录
查看更多内容
DOI：
10.1007/s13300-013-0040-0
发表时间：
2013-12
期刊：
Diabetes therapy : research, treatment and education of diabetes and related disorders
影响因子：
--
作者：
Davidson JA
通讯作者：
Davidson JA
影响因子：
4.5
作者：
Kubota Y;Miyamoto M;Takagi G;Ikeda T;Kirinoki-Ichikawa S;Tanaka K;Mizuno K
通讯作者：
Mizuno K
影响因子：
7.7
作者：
Iwaki, M;Matsuda, M;Shimomura, I
通讯作者：
Shimomura, I
影响因子：
9.3
作者：
Hibuse, Toshiyuki;Maeda, Norikazu;Shimomura, Iichiro
通讯作者：
Shimomura, Iichiro
影响因子：
8.7
作者：
Hotta, K;Funahashi, T;Matsuzawa, Y
通讯作者：
Matsuzawa, Y